Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood test can predict long-term risk of death in patients with shortness of breath

14.02.2006


Researchers from Massachusetts General Hospital (MGH) have shown that a blood test previously found useful for diagnosing heart failure and determining prognosis in several cardiovascular conditions can also predict the risk of death among patients coming to hospital emergency departments with shortness of breath. Their report in the Feb. 14 Archives of Internal Medicine describes how measuring levels of a protein called NT-proBNP was the most powerful predictor of whether patients would die within the year.


"We found that, regardless of whether the patient had been diagnosed with heart failure, elevated levels of this protein were strongly prognostic for death at one year and low levels identified those at the lowest risk," says James Januzzi Jr., MD, of the MGH Cardiology Division, the paper’s lead author. "Based on these results, we recommend that every patient coming to a hospital with shortness of breath be tested for NT-proBNP."

NT-proBNP is a natriuretic peptide, a protein produced when the cardiac muscle is under stress. In recent years these proteins have been investigated as assays for various forms of cardiovascular disease. In April 2005, members of the same MGH research team published the PRIDE study, which enrolled almost 600 patients who came to the MGH Emergency Department with shortness of breath. The PRIDE study showed that emergency department testing for NT-proBNP could help diagnose heart failure in those patients, providing a definitive diagnosis when the result was above specific levels and ruling it out when results were below an identified point.

The current study, designed to evaluate the long-term prognostic usefulness of the test, followed up on the patients in the PRIDE study. The research team contacted primary care physicians or cardiologists for each of the study participants, or reviewed hospital records, to determine their status a year after the original emergency visit. The results, which included data from all but four of the PRIDE study participants, showed that the NT-proBNP measurement made in the emergency department was a more accurate predictor of the risk of death during the following year than were other known measurements of cardiac risk.



"One of the more impressive findings in our study was the remarkably strong prognostic ability of NT-proBNP measurement in patients with shortness of breath from all causes," Januzzi added. "An elevated NT-proBNP was as strong a predictor of death in patients without heart failure as it was for those with it. And remarkably, among those found to have heart failure in the original visit, no patient with an NT-proBNP level below a certain point died during the study period.

"Elevations of NT-proBNP can be used not only to determine the diagnosis and the best hospital setting for treatment but also to estimate longer-term prognosis, allowing us to identify patients needing more intensive treatment and follow-up," he adds. "The next logical step is to evaluate treatment interventions for those with higher NT-proBNP levels to see if we can reduce their considerable risk for death." Januzzi is currently directing a randomized clinical trial of medical therapy guided by NT-proBNP measurement for patients with recent heart failure.

The study’s coauthors are Rahul Sakhuja, MD, MPP, Michelle O’Donoghue, MD, Aaron Baggish, MD, Saif Anwaruddin, MD, Claudia Chae, MD, MPH, Renee Cameron, Daniel Krauser, MD, Roderick Tung, MD, and Carlos Camargo Jr., MD, of MGH, and Donald Lloyd-Jones, MD, ScM, of the Feinberg School of Medicine at Northwestern University. The study was supported by a grant from Roche Diagnostics, which manufacturers the NT-proBNP assay studied but had no role in conducting the investigation or reporting the results.

Sue McGreevey | EurekAlert!
Further information:
http://www.mgh.harvard.edu/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>